摘要
目的 探讨妇女尿中MMP-9及MMP-9，NGAL复合物的表达，对乳腺癌高危发病的妇女是否具有普查筛选意义。方法：采用明胶酶底物电泳法、Western blot方法，检测正常女性（n=601、乳腺良性疾病病人（n=41）、乳腺癌病人（n=127）的尿液中的MMP-9及MMP-9／NGAL复合物的表达状况。结果 MMP-9及其MMP-9／NGAL复合物的表达。在正常女性尿中分别15％，13．33％；乳腺良性疾病病人尿中分别为39．02％，36．59％；乳腺癌病人尿中分别为76．37％，70．08％。乳腺癌病人尿中MMP-9及其MMP-9／NGAL复合物的表达，与正常女性比较差异非常显著（p〈0．001）；与乳腺良性疾病比较差异也非常显著（p〈0．01）。早期乳腺癌病人尿中MMP-9＋MMP-9／NGAL复合物同时表达，与乳腺良性疾病比较差异非常显著（p〈0．01）。结论 （1）乳腺癌、乳腺良性疾病和正常人MMP-9及其MMP-9／NGAL复合物都有表达。但正常人很少表达MMP-9，极少表达MMP-9／NGAL复合物。（2）乳腺癌病人尿中MMP-9＋MMP-9／NGAL复合物的同时表达。对乳腺癌的早期诊断具有重要意义。对乳腺癌高危发病妇女的普查筛选具有指导意义。
Objectives To explore the potentialities of urinary MMP-9 and MMP-9/NGAL complex as screening biomakers of breast cancer in high-risk patient population. Methods Urinary MMP-9 and MMP-9/NGAL complex were detected using substrate zymography gel electrophoresis end their molecular identity was confirned with Western blot analysis.Urine samples were collected from healthy women （n=60）,patrents with benign breast disease （n=41）, or patients with breast cancel （n=127）. Results The expression of MMP-9 and MMP-9/NGAL complex were detected in 15% and 13.33% of normal women; 39.02% and 36.59% of patients with benign breast disease ; 76.37% and 70.08% of breast cancer patients respectively. BR：ast cancer patients as compared to normal women （p〈0.001）, or patients with benign breast disease （p〈0.01, the presence of all three urinary MMP-9 and MMP-9/NGAL complex, was significantly higher. The urine MMP-9/NGAL complex expressed simultaneously in patients with early stage breast cancer with significant difference with those in patients with benign breast disease （p〈0.01）. Conclusions （1）Three urinary MMP-9 and MMP-9/NGAL complex activities were detected in patients with breast cancer, in patients with benign breast disease and in normal women. But MMP-9 and MMP-9/NGAL complex activities were rarely detected in normal women.（2）Detection of all three urinary MMP-9, and MMP-9/NGAL complex may be used as an early diagnosis method for breast cancer and as screening makers of early breast cancer in high-risk patient population.
